JPRN-jRCT2080221270未知2 期
A Safety and Efficacy Extension Study of ONO-4641 in Patients with Relapsing-Remitting Multiple Sclerosis
ONO PHARMACEUTICAL CO.,LTD.0 个研究点目标入组 343 人开始时间: 2010年10月18日最近更新:
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 343
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 <= 55age old（—）
- 性别
- All
入选标准
- •Completed 26 weeks of double-blind phase of Study ONO-4641POU006
排除标准
- •Presence of any dermatological abnormalities during Study ONO-4641POU006 that could increase the risk of the patient developing a skin cancer.
研究者
相似试验
进行中（未招募）
不适用
A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSISEUCTR2010-018705-11-GRONO Pharmaceutical Co., Ltd.376
进行中（未招募）
不适用
A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSISRelapsing-remitting Multiple SclerosisMedDRA version: 17.0Level: PTClassification code 10063399Term: Relapsing-remitting multiple sclerosisSystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-018705-11-CZMerck KGaA376
进行中（未招募）
不适用
A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSISEUCTR2010-018705-11-DEMerck KGaA376
进行中（未招募）
不适用
A SAFETY AND EFFICACY EXTENSION STUDY OF ONO-4641 IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSISEUCTR2010-018705-11-BEMerck Serono S.A. - Geneva376
终止
2 期
Phase 2 Extension Trial in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS)Multiple SclerosisNCT01226745EMD Serono340